HRS9531 placebo

DRUG2 trials

Sponsors

Shanghai Zhongshan Hospital, Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions

Atherosclerotic Cardiovascular DiseaseObesity

Phase 2

HRS9531 Controls Weight Regain in Obese Subjects

Active, not recruitingNCT06287437

Shanghai Zhongshan HospitalObesity

Start: 2024-01-01End: 2025-12-31Target: 72Updated: 2024-03-01

Phase 3

A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

RecruitingNCT07551492

Fujian Shengdi Pharmaceutical Co., Ltd.Atherosclerotic Cardiovascular Disease

Start: 2026-05-29End: 2031-06-28Target: 9262Updated: 2026-09-08